Winners with ALS, SMA and LGMD receive support to pursue postgraduate education
Three accomplished scholars determinedly pursuing their educations while living with neuromuscular disease are the first winners of the CMMS Deshae Lott Ministries outreach program scholarships.
“We were so impressed,” with the winning candidates, said Deshae Lott, 39, a teacher and minster from Bossier City, La., who founded the nonprofit that bears her name. “These three show great strength of...
News on amyotrophic lateral sclerosis, congenital muscular dystrophy, Friedreich's ataxia and spinal muscular atrophy
Amyotrophic lateral sclerosis (ALS)
Reports on research in amyotrophic lateral sclerosis, Duchenne muscular dystrophy, myotubular myopathy and spinal muscular atrophy
Duchenne muscular dystrophy
Acceleron Pharma announced Aug. 4 that it has received fast track designation from the U.S. Food and Drug Administration (FDA) for its experimental compound ACE031 for the treatment of Duchenne muscular dystrophy (DMD). ACE031 is designed to interfere with the actions of myostatin, a protein that inhibits muscle growth.
Researchers have identified a compound that helps cells produce more full-length SMN protein from the backup SMN2 gene.
Scientists have identified a chemical cousin of the commonly used antibiotic tetracycline that has the potential to be refined and modified into a therapy for spinal muscular atrophy (SMA).
PTK-SMA1 works by correcting an error in a cellular process called RNA splicing, and leads to increased production of a critical protein that is deficient in this disease.
A variant in the SMN2 gene leads to more full-length SMN protein and better function
Scientists have uncovered a variant (mutation) in the SMN2 gene that leads to production of more full-length SMN protein molecules and a milder version of spinal muscular atrophy (SMA). The finding, a naturally occurring point mutation (a single letter change in the DNA code) in this gene, has immediate implications for genetic testing and possible long-term implications for therapy development.
Ms. Wheelchair Michigan spreads message of self-advocacy and inclusion
Morgan Fritz has a clear idea what her role will be as the 2005 MDA National Goodwill Ambassador. "To talk a lot," she says with a smile.
But rest assured: The charming 6-year-old from St. Peters, Mo., knows exactly what to talk about when she and her family represent MDA and its clients nationwide this year.
Morgan will attend fund-raisers, sponsor gatherings and other events to spread the word...